Full Press Release Details
ANDOVER, Mass., Oct. 30, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on October 28, 2026, the Company granted non-qualified stock options to purchase an aggregate of 71,815 shares of its common stock and an aggregate of 47,924 restricted stock units (RSUs) to nine employees. These awards were granted as a material inducement for each employee's entry into employment with TransMedics.
The grants included stock options to purchase 34,419 shares of TransMedics' common stock and 22,969 RSUs granted to Fernando Araujo, the Company's Chief Financial Officer. The grants were approved by the Compensation Committee of the TransMedics Board of Directors and granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the TransMedics Group, Inc. Inducement Plan.
The stock options were granted with a per share exercise price of $66.90, the closing price of the common stock on the Nasdaq Global Market on October 28, 2026. Twenty-five percent of the shares subject to each option grant will vest on the first anniversary of the date of the employee's start of employment, with the remainder vesting in equal monthly installments over the subsequent three-year period, subject to the employee's continued service with the Company through the applicable vesting date. The options have a 10-year term and are subject to the terms of the TransMedics Group, Inc. Inducement Plan. Twenty-five percent of each RSU award will vest on the first four anniversaries of the date of the employee's start of employment, subject to the employee's continued service with the Company through the applicable vesting date. The RSUs are subject to the terms of the TransMedics Group, Inc. Inducement Plan.
About TransMedics Group, Inc. TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.